Download Files:
Mal-PEG8-Phe-Lys-PAB-Exatecan (TFA)
$450 – $2,350
Products Details
Product Description
– Mal-PEG8-Phe-Lys-PAB-Exatecan TFA is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631)[1].
Web ID
– HY-148380A
Storage Temperature
– -20°C (Powder, protect from light)
Shipping
– Blue Ice
Applications
– Cancer-programmed cell death
Molecular Formula
– C75H93F4N9O22
References
– [1]Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1. |[2]Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1.
Molecular Weight
– 1548.58
Compound Purity
– 98.44
SMILES
– O=C(C=CC1=O)N1CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCCN)C(NC(C=C3)=CC=C3COC(N[C@@H]4C5=C6C(C(N7C6)=CC([C@](O)(C(OC8)=O)CC)=C8C7=O)=NC9=CC(F)=C(C)C(CC4)=C95)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Drug-Linker Conjugates for ADC
Pathway
– Antibody-drug Conjugate/ADC Related
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
